Tethis has entered a research collaboration with Weill Cornell Medicine to use Tethis' liquid biopsy platform in monitoring treatment response in early-stage breast cancer patients.

The research study will take place at both Tethis and Dr. Massimo Cristofanilli's lab at Weill Cornell Medicine and aims to gain more insight into the science of tumor evolution and guide decision-making in treatment. It involves collecting blood samples from patients to examine the type and quantity of tumor cells and DNA discharged into the bloodstream. The sample data will then be analyzed and compared against the actual treatment outcomes of the patients. The results are expected to provide insights aiding in the creation of personalized treatments for early-stage breast cancer patients. 

Italy-based Tethis S.p.A. specializes in developing liquid biopsy testing technology. The company's flagship product, See.d, is a universal blood sample preparator designed to standardize and automate the pre-analytical process for comprehensive liquid biopsy analysis. It processes fresh blood collected in EDTA tubes, separates plasma from the cellular fraction, performs red blood cell lysis and removal, and dispenses and fixes white blood cells on proprietary nanocoated SBS slides, producing a fixed monolayer of all white blood cells on SBS slides and a separate tube containing the plasma aliquot, which is claimed to be stable for several days post-separation.